{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:29:04Z","timestamp":1793834944255,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFC2501205"],"award-info":[{"award-number":["2021YFC2501205"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,071,428"],"award-info":[{"award-number":["82,071,428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,171,412"],"award-info":[{"award-number":["82,171,412"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.neuroscience.2024.12.056","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T12:00:56Z","timestamp":1735560056000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Increased \u03b1-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson\u2019s disease"],"prefix":"10.1016","volume":"567","author":[{"given":"Na","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeyun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"40","key":"10.1016\/j.neuroscience.2024.12.056_b0005","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-017-0452-6","article-title":"Mechanisms underlying extensive Ser129-phosphorylation in \u03b1-synuclein aggregates","volume":"5","author":"Arawaka","year":"2017","journal-title":"Acta. Neuropathol. Commun."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2013.09.061","article-title":"In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 \u03b1-synuclein phosphorylation in mouse brain","volume":"256","author":"Bergeron","year":"2014","journal-title":"Neuroscience"},{"issue":"10291","key":"10.1016\/j.neuroscience.2024.12.056_b0020","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.12.056_b0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.12.056_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinson's disease-related pathology","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00080","article-title":"Mechanisms of \u03b1-Synuclein Induced Synaptopathy in Parkinson's Disease","volume":"12","author":"Bridi","year":"2018","journal-title":"Front. Neurosci."},{"issue":"29","key":"10.1016\/j.neuroscience.2024.12.056_b0040","doi-asserted-by":"crossref","first-page":"20313","DOI":"10.1074\/jbc.274.29.20313","article-title":"Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid","volume":"274","author":"Chalfant","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuroscience.2015.05.035","article-title":"\u03b1-Synuclein-induced internalization of NMDA receptors in hippocampal neurons is associated with reduced inward current and Ca(2+) influx upon NMDA stimulation","volume":"300","author":"Chen","year":"2015","journal-title":"Neuroscience"},{"issue":"13","key":"10.1016\/j.neuroscience.2024.12.056_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310932","article-title":"Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease","volume":"24","author":"Cocco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.neuroscience.2024.12.056_b0055","doi-asserted-by":"crossref","first-page":"15523","DOI":"10.1016\/S0021-9258(18)82288-8","article-title":"Ceramide activates heterotrimeric protein phosphatase 2A","volume":"268","author":"Dobrowsky","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0060","doi-asserted-by":"crossref","unstructured":"Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of \u03b1-Synuclein Oligomers in Parkinson's Disease. Int. J. Mol. Sci. 21(22). doi: ARTN 864510.3390\/ijms21228645.","DOI":"10.3390\/ijms21228645"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.12.056_b0065","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on \u03b1-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.12.056_b0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/emm.2001.39","article-title":"Effects of cations on ceramide-activated protein phosphatase 2A","volume":"33","author":"Galadari","year":"2001","journal-title":"Exp. Mo.l Med."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0075","doi-asserted-by":"crossref","unstructured":"Gan-Or, Z., Liong, C., and Alcalay, R.N. (2018). GBA-Associated Parkinson's Disease and Other Synucleinopathies. Curr. Neurol. Neurosci. Rep. 18(8). doi: ARTN 4410.1007\/s11910-018-0860-4.","DOI":"10.1007\/s11910-018-0860-4"},{"issue":"50","key":"10.1016\/j.neuroscience.2024.12.056_b0080","doi-asserted-by":"crossref","first-page":"49071","DOI":"10.1074\/jbc.M208046200","article-title":"Phosphorylated \u03b1-synuclein is ubiquitinated in \u03b1-synucleinopathy lesions","volume":"277","author":"Hasegawa","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.neuroscience.2024.12.056_b0085","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1074\/jbc.C800206200","article-title":"Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system","volume":"284","author":"Inglis","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.12.056_b0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2188\/jea.12.280","article-title":"Demographic determinants for change in activities of daily living: a cohort study of the elderly people in Beijing","volume":"12","author":"Jiang","year":"2002","journal-title":"J. Epidemiol."},{"issue":"11","key":"10.1016\/j.neuroscience.2024.12.056_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116216","article-title":"Pathogenic Impact of \u03b1-Synuclein Phosphorylation and Its Kinases in \u03b1-Synucleinopathies","volume":"23","author":"Kawahata","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.neuroscience.2024.12.056_b0100","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced Phosphatase Activity Attenuates \u03b1-Synucleinopathy in a Mouse Model","volume":"31","author":"Lee","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.623977","article-title":"Alterations of Erythrocytic Phosphorylated Alpha-Synuclein in Different Subtypes and Stages of Parkinson's Disease","volume":"13","author":"Li","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0110","article-title":"Inhibition of \u03b1-Synuclein Accumulation Improves Neuronal Apoptosis and Delayed Postoperative Cognitive Recovery in Aged Mice","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0115","doi-asserted-by":"crossref","unstructured":"Lin, C.H., Liu, H.C., Yang, S.Y., Yang, K.C., Wu, C.C., and Chiu, M.J. (2019). Plasma pS129-\u03b1-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease. J. Clin. Med. 8(10). doi: ARTN 160110.3390\/jcm8101601.","DOI":"10.3390\/jcm8101601"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.12.056_b0120","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.neurobiolaging.2015.06.004","article-title":"Increased oligomerization and phosphorylation of \u03b1-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains","volume":"36","author":"Liu","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.12.056_b0125","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1021\/acschemneuro.8b00383","article-title":"Alpha-Synuclein in Peripheral Tissues in Parkinson's Disease","volume":"10","author":"Ma","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mcn.2018.12.005","article-title":"Cerebrospinal fluid biomarker for Parkinson's disease: An overview","volume":"97","author":"Maass","year":"2019","journal-title":"Mol. Cell Neurosci."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.12.056_b0135","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1074\/jbc.M109.081950","article-title":"Phosphorylation of Synucleins by Members of the Polo-like Kinase Family","volume":"285","author":"Mbefo","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.12.056_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JPD-160779","article-title":"Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?","volume":"6","author":"Oueslati","year":"2016","journal-title":"J. Parkinsons Dis."},{"issue":"10","key":"10.1016\/j.neuroscience.2024.12.056_b0145","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s10072-020-04407-4","article-title":"Peripheral neuropathy in Parkinson's disease","volume":"41","author":"Paul","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.175","article-title":"Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase 2A activation","volume":"5","author":"P\u00e9rez-Revuelta","year":"2014","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.neuroscience.2024.12.056_b0155","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0160","doi-asserted-by":"crossref","unstructured":"Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 8(4). doi: ARTN 36410.3390\/cells8040364.","DOI":"10.3390\/cells8040364"},{"issue":"7","key":"10.1016\/j.neuroscience.2024.12.056_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","article-title":"Alpha synuclein is transported into and out of the brain by the blood-brain barrier","volume":"62","author":"Sui","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.neuroscience.2024.12.056_b0175","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fgene.2014.00382","article-title":"Phosphatases of \u03b1-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism","volume":"5","author":"Taymans","year":"2014","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.12.056_b0180","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","article-title":"Initiation and progression of \u03b1-synuclein pathology in Parkinson's disease","volume":"79","author":"Tofaris","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0185","article-title":"Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity","volume":"2016","author":"Wang","year":"2016","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105291","article-title":"In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129","volume":"152","author":"Weston","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.neuroscience.2012.01.028","article-title":"Lewy-like aggregation of \u03b1-synuclein reduces protein phosphatase 2A activity in vitro and in vivo","volume":"207","author":"Wu","year":"2012","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.12.056_b0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.13234","article-title":"The phosphorylation of \u03b1-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease","volume":"135","author":"Xu","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1042\/bse0560125","article-title":"Role of \u03b1-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease","volume":"56","author":"Yu","year":"2014","journal-title":"Essays Biochem."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2018.10.003","article-title":"Phosphorylated \u03b1-synuclein deposits in sural nerve deriving from Schwann cells: A biomarker for Parkinson's disease","volume":"60","author":"Zhang","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2024.12.056_b0215","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224007632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224007632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:04:57Z","timestamp":1774260297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224007632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"alternative-id":["S0306452224007632"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.12.056","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased \u03b1-synuclein phosphorylation and oligomerization and altered enzymes in plasma of patients with Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.12.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}